Division of Allergology, Clinic for Rheumatology and Clinical Immunology/Allergology, Inselspital, University of Bern, CH-3010 Bern, Switzerland.
Med Clin North Am. 2010 Jul;94(4):645-64, xv. doi: 10.1016/j.mcna.2010.04.003.
Small molecules, used as drugs, can induce immune reactions by binding covalently as haptens to a carrier protein, which is thereby modified and immunogenic. In addition, drugs bind to proteins via hydrogen bonds, electrostatic force, and van der Waals forces, and may directly interact with immune receptors such as T cell receptors or major histocompatibility complex molecules (pharmacologic interaction with immune receptors, so-called p-i concept). Even this noncovalent interaction may stimulate T cells. The ensuing immune response based on hapten-peptide presentation or direct drug-receptor interaction results in many distinct clinical situations. Based on progress in T cell immunology, this heterogeneity of T cell reaction is now also reflected in a subclassification of type IVa to IVd reactions.
小分子作为药物,可以通过共价结合到载体蛋白上作为半抗原来诱导免疫反应,从而使载体蛋白发生改变并具有免疫原性。此外,药物通过氢键、静电力和范德华力与蛋白质结合,并且可能直接与免疫受体(如 T 细胞受体或主要组织相容性复合体分子)相互作用(与免疫受体的药物相互作用,所谓的 p-i 概念)。即使是非共价相互作用也可能刺激 T 细胞。基于半抗原-肽呈递或直接药物-受体相互作用的免疫反应导致许多不同的临床情况。基于 T 细胞免疫学的进展,这种 T 细胞反应的异质性现在也反映在 IVa 至 IVd 型反应的亚分类中。